Bryant Furlow

Contributing Writer https://www.cancertherapyadvisor.com

Bryant Furlow is a contract medical journalist for the Haymarket Medical Network. He holds a bachelor of science in biology (summa cum laude) from the University of New Mexico. He covers radiation oncology, immunotherapy, tumor biology, clinical research, and health care policy. Prior to becoming a contributor to Haymarket Media in 2010, Bryant was a newspaper reporter in New Mexico, where he won awards for public health and investigative journalism. He also reports for The Lancet Oncology news desk.

All articles by Bryant Furlow

$Ultrahypofractionated SBRT can deliver radiotherapeutic doses in 2 weeks or fewer without increasing toxicity risk, according to findings from PACE-B.$

Prostate Cancer

Ultrahypofractionated SBRT Prostate Cancer Radiotherapy Does Not Increase Radiotoxicities

Bryant Furlow

November 5, 2019

Ultrahypofractionated SBRT can deliver radiotherapeutic doses in 2 weeks or fewer without increasing toxicity risk, according to findings from PACE-B.

The high cost of CAR-T therapy concerns patient advocates who worry about the "financial toxicity" i

Multiple Myeloma

Analysis Determines Cost Effectiveness of Various Treatment Strategies for Multiple Myeloma

Bryant Furlow

October 10, 2019

In this systematic review, researchers analyzed the cost effectiveness of various treatments and treatment lines for multiple myeloma.

Managing adverse effects after starting a TKI can be challenging, and health care practitioners ofte

ESMO 2019

Single-Agent Immunotherapies Carry Different irAE Risks

Bryant Furlow

October 1, 2019

“Despite a lack of head-to-head trials, there is a perception that irAE profiles are
comparable between agents,” the abstract authors wrote.

Patients younger than 50 years with NSCLC were more likely to have a targetable genomic alteration.

ESMO 2019

Immunotherapy irAEs Associated With Hospitalizations, Treatment Discontinuation

Bryant Furlow

October 1, 2019

More than 15,000 distinct irAEs were found for 13,030 patients.

The Leukemia & Lymphoma Society partnered with Sutro Biopharma to test the safety of the investigati

ESMO 2019

Blood Test May Potentially Replace Invasive Biopsy for Certain Patients With Lung Cancer: Results of BFAST

Bryant Furlow

October 1, 2019

Liquid biopsy can be used to detect a complex type of driver mutation, called ALK, in patients with NSCLC.

ESMO 2019

Pembrolizumab Does Not Outperform Chemotherapy in Mesothelioma

Bryant Furlow

September 30, 2019

While pembrolizumab was not superior to chemotherapy, survival times were similar, suggesting immunotherapy might offer an alternative to chemotherapy.

Patients with breast cancer report financial barriers to quality care and provide suggestions for alleviating the economic burdens of the disease.

ESMO 2019

Palbociclib, Capecitabine Regimens Offer Similar Patient-Reported Quality-of-Life Outcomes in Metastatic HR-Positive Breast Cancer

Bryant Furlow

September 30, 2019

Results of the YoungPearl study revealed that patient-reported QoL scores were high for palbociclib plus endocrine therapy.

Trastuzumab emtansine reduces the risk of recurrence by 50% in some HER2-positive breast cancers following neoadjuvant chemotherapy.

ESMO 2019

Abemaciclib Plus Fulvestrant Improved Survival in Patients with HR+, HER2- Advanced Breast Cancer

Bryant Furlow

September 30, 2019

Results of MONARCH-2 showed a statistically significant and clinically meaningful improvement in overall survival with abemaciclib plus fulvestrant.

ESMO 2019

Pembrolizumab Does Not Prolong Survival Compared With Chemotherapy in Metastatic TNBC

Bryant Furlow

September 29, 2019

Pembrolizumab monotherapy does not improve overall survival (OS) compared with single-agent chemotherapy among women with metastatic triple negative breast cancer (mTNBC).